期刊文献+

替吉奥胶囊联合顺铂治疗晚期胃癌的疗效观察 被引量:3

To Observe the Curative Effect of S-1 Combined With Cisplatin in Treatment of Advanced Gastric Cancer
下载PDF
导出
摘要 目的 探究晚期胃癌患者的临床治疗中替吉奥胶囊和顺铂联合应用效果。方法 2014年7月~2015年12月,我院接受诊治的晚期胃癌患者86例随机分为对照组和观察组,对照组患者应用替吉奥胶囊治疗,观察组患者在此基础上联合顺铂治疗。结果 观察组患者的近期治疗效果高于对照组,同时观察组患者的不良反应发生率低于对照组,差异具有统计学意义(P〈0.05)。结论 在晚期胃癌患者的临床治疗中结合替吉奥胶囊和顺铂治疗均能够显著改善患者的近期治疗效果,同时降低不良反应发生率。 Objective To explore the clinical treatment of S-1 and cisplatin in patients with advanced gastric carcinoma combined application effect. Methods From July 2014 to December 2015, 86 cases of patients with advanced gastric cancer were randomly divided into control group and observation group respectively in our hospital, control group were treated with S-1 capsule in the treatment of observed group patients on the basis of the combined with cisplatin. Results The short-term treatment effect of the observation group was significantly higher than that of the control group, the incidence of adverse reactions in the observation group was significantly lower than that in the control group, the difference was statistically significant (P〈0.05). Conclusion In the clinical treatment of patients with advanced gastric cancer combined with S-1 capsule and cisplatin in the treatment can significantly improve the patient's therapeutic effect in the near future, at the same time, reduce the incidence of adverse reactions, it is worth popularization and application in clinical treatment.
作者 袁航 任统伟
出处 《中国继续医学教育》 2016年第26期181-182,共2页 China Continuing Medical Education
关键词 替吉奥胶囊 顺铂 晚期胃癌 疗效 S-1 capsule, Cisplatin, Advanced gastric cancer, Curative effect
  • 相关文献

参考文献9

二级参考文献50

  • 1秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:268
  • 2智玲玲,刘威.多西他赛联合卡铂治疗老年晚期胃癌43例[J].实用诊断与治疗杂志,2007,21(8):617-618. 被引量:2
  • 3Malel-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil(capecitabine,UFT,S-1) :a review[J]. Oncologist,2002,7 (4) :288-323.
  • 4Tanaka F, Fukuse T, Wada H, et al. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents[J]. Curt Pharm Biotechnol, 2000,1 (2) : 137-164.
  • 5Jin M, Lu H, Li J ,et al. Randomized 3-armed phase Ⅲ study of S- 1 monotherapy vesus S-1/CDDP (SP) vesus 5-Fu/CDDP (FP) in patients(pts) with advaneed gastric cancer (AGC) : SC101 study [J]. J ClinOncol,2008, 26: a4553.
  • 6Ajanj Ja. Docetaxel for gastric and esophageal carcinomas. Oncology,2002, 16 (6) : 89-96.
  • 7Tanaka F, Fukuse T,Wada H, et al. The history, mechanism and clinical use of oral 5-fluoroumcil derivative chemotherapeutic agents. Curr Pharm Biotechnol, 2000, 1 (2) : 137-164.
  • 8Terashima M, Fujiwara H, Takagane A, et al. Prediction of sensitivity to fluoropy rimidines bymetabolic and target enzyme activities in gastric cancer. Gastric Cancer, 2003, 6 ( Suppl 1) :71- 81.
  • 9Yoshisue K, Hironaga K, Yamaguehi S, et al. Reducti on of 5- fluorouracil gastrointestinal ( GI ) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated repeated simultaneous administration of potassium oxonate (Oxo) in rats. Cancer Chemother Phar macol, 2000, 46 (1) : 51-56.
  • 10Yoshisue K, Masuda H,Matsushima E, et al. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent ( drug combination of tegafur, 5-chloro 2, 4 dihydr oxypyridine, and potassium oxonate ) to rats. Drug Metab Dispos, 2000, 28 (10) : 1162-1167.

共引文献70

同被引文献17

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部